EU Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market, Market Segmented by Drug Class ( Glycopeptides and Lipoglycopeptides, Oxazolidinones, Lipopeptides, Cephalosporin, Tetracycline, and Others), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)- Growth, Trends and Forecast, 2019-2028
- Published Date: 2022-12-26
- Report ID: 138174
- Pages: 200
-
Format:
Report Overview
The EU Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period
Methicillin-resistant staphylococcus aureus (MRSA) is an infection caused by antibiotic-resistant strains of the pathogen staphylococcus aureus. Methicillin-resistant Staphylococcus aureus (MRSA) can be divided into two types based on the mode of infection hospital-associated MRSA infection (HA-MRSA) and community-associated MRSA infections (CA-MRSA). This infection is mainly associated with invasive procedures such as surgeries, intravenous tubing, and sometimes through the skin to skin contact. MRSA drugs are used to kill or restrain Methicillin-resistant staphylococcus aureus infection
Market Drivers
Growing incidence of infections associated with Methicillin-resistant staphylococcus aureus (MRSA) pathogens is creating health concerns among the population. Manufacturers are focusing on product development and launches for the treatment of Methicillin-resistant staphylococcus aureus (MRSA), which is expected to boost the Methicillin-resistant staphylococcus aureus (MRSA) drugs market growth. Rising number of pipeline products for MRSA drugs is also a major factor that is expected to boost growth of the Methicillin-resistant staphylococcus aureus (MRSA) drugs
1. EU Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Overview
A. Market Size
2. EU Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Growth Drivers.
A. Increasing product launches and approvals are expected to drive the market growth over the forecast period
B. Furthermore, adoption of inorganic growth strategies such as merger, acquisition, collaborations by key players
3. EU Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Segmentation
A. By Drug Class
I. Glycopeptides and Lipoglycopeptides
II. Oxazolidinones
III. Lipopeptides
IV. Cephalosporin
V. Tetracycline
VI. Others
B. By Distribution Channel
I. Hospital Pharmacies
II. Retail Pharmacies
III. Online Pharmacies
4. EU Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Major Market Share
A. Market Analysis, Insights and Forecast by Revenue
5. Competitive Landscape
A. Major Players
B. Products in Pipeline
6. Key Company Profiles..
A. Merck & Co, Company overview, Product & Services, Strategies & Financials
B. Pfizer Inc, Company overview, Product & Services, Strategies & Financials
C. Novartis, Company overview, Product & Services, Strategies & Financials
7. Healthcare Policies and Regulatory Landscape.
A. Policy Changes and Reimbursement Scenario
8. Factors Driving Market Growth
A. Key Industry Developments
B. Mergers and Acquisitions
9. Potential Growth Opportunities
A. Market Opportunities
B. Future Trends
10. Conclusion
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
